GW Pharmaceuticals plc GWPH

GW Pharmaceuticals plc Revenue 2011-2026 | GWPH

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue GW Pharmaceuticals plc

2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
527 M	311 M	12.7 M	11 M	13.4 M	43.2 M	48.8 M	44.1 M	53.5 M	46.2 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
527 M	11 M	111 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
ACADIA Pharmaceuticals ACAD	958 M	$ 22.56	2.13 %	$ 3.74 B	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
argenx SE ARGX	36.4 M	$ 785.07	2.57 %	$ 25 B	Niderland
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
Akebia Therapeutics AKBA	236 M	$ 1.43	3.62 %	$ 368 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Alnylam Pharmaceuticals ALNY	3.71 B	$ 327.25	2.42 %	$ 42.9 B	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Applied Therapeutics APLT	9.99 M	-	-	$ 8.42 M	USA
Alterity Therapeutics Limited ATHE	109 K	$ 3.9	3.7 %	$ 9.38 B	Australia
Autolus Therapeutics plc AUTL	75.4 M	$ 1.49	9.56 %	$ 397 M	Britain
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	720 M	$ 20.4	-0.87 %	$ 954 M	USA
Aquestive Therapeutics AQST	44.5 M	$ 4.18	1.21 %	$ 447 M	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	66.4 M	$ 2.66	3.5 %	$ 16.7 M	USA
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain
Arcutis Biotherapeutics ARQT	376 M	$ 24.61	5.76 %	$ 3.13 B	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
BeiGene, Ltd. BGNE	5.34 B	-	0.49 %	$ 251 B	Cayman-islands
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Cabaletta Bio CABA	0.006	$ 3.09	0.65 %	$ 310 M	USA
CymaBay Therapeutics CBAY	31.1 M	-	-	$ 3.45 B	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Codiak BioSciences CDAK	22.9 M	-	-55.98 %	$ 2.15 M	USA
Avid Bioservices CDMO	140 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	1.28 M	-	-	$ 1.41 B	USA
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
Checkpoint Therapeutics CKPT	41 K	-	-	$ 169 M	USA
Celldex Therapeutics CLDX	1.54 M	$ 32.41	3.38 %	$ 2.15 B	USA
Celsion Corporation CLSN	500 K	-	-6.63 %	$ 13.9 M	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Chimerix CMRX	324 K	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	7.9 M	-	-	$ 401 M	USA